scholarly journals The effect of short-term low-energy ultraviolet B irradiation on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis: A randomized single-blinded controlled clinical trial

2013 ◽  
Vol 141 (9-10) ◽  
pp. 615-622 ◽  
Author(s):  
Ivan Micic ◽  
In-Ho Jeon ◽  
So-Hyun Park ◽  
Seo-Sung Hwa ◽  
Jae-Myeung Chun ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Turnover Markers ◽  
Low Energy ◽  
Controlled Clinical Trial ◽  
Mineral Density ◽  
Short Term ◽  
Turnover Markers

Introduction. The importance of vitamin D on bone health and osteoporosis was studied by many researchers. The main role of the Vitamin D is to absorb calcium and phosphate and increase bone mineralization. Older people are at an increased risk of the inadequate vitamin D production in the skin because of lower sun exposure and reduced ability of the skin to synthesize vitamin D. Objective. The aim of this clinical trial was to evaluate the efficacy and tolerability of short-term (2 weeks) low energy UVB irradiation in postmenopausal women with osteoporosis using bone mineral density and bone turnover markers. Methods. A three-month, single-blinded, randomized, placebo-controlled clinical trial was conducted at the University hospital in Daegu, Republic of Korea. Fifty-two postmenopausal Korean women (older than 65 years) with osteoporosis were randomly allocated to have either low energy UVB or placebo for 30 minutes a day for two weeks of treatment during winter. Laboratory analysis and physical examination before and 4, 8 and 12 weeks after treatment were carried out and BMD was measured before and 8 and 12 weeks after treatment. The effects of time and treatment interaction between these two groups were evaluated by repeated-measure two-factor analysis, and subgroup analysis was performed to examine UVB effect on the vitamin D insufficient group [serum 25(OH)D3 concentration <30 ng/mL]. Results. In vitamin D insufficient group, the effect of UVB irradiation on vitamin D and bone ALP as well as additional benefit on bone formation was confirmed. The vitamin D insufficient group showed statistically significant increment in serum 25(OH)D3 compared with the normal group (p<0.05). However, there was no significant difference between two groups in the other bone turnover markers, such as serum calcium, PTH-C, serum osteocalcin, serum CTX and BMD. Conclusion. Low-energy-short-term UVB radiation for postmenopausal women may be of use in vitamin D synthesis. There was a modest benefit in change of bone ALP especially in women with the insufficient vitamin D.

scholarly journals Vitamin D Metabolites and Sex Steroid Indices in Postmenopausal Women with and without Low Bone Mass

Metabolites ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 86
Author(s):  
Nasser M. Al-Daghri ◽  
Sobhy M. Yakout ◽  
Mohammed G.A. Ansari ◽  
Syed D. Hussain ◽  
Kaiser A. Wani ◽  
...  
Keyword(s):  
Vitamin D ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Sex Hormones ◽  
Bone Turnover Markers ◽  
Vitamin D Metabolites ◽  
Mineral Density ◽  
Skeletal Health ◽  
Normal Bone Mineral Density ◽  
Turnover Markers

While the independent roles of vitamin D and sex hormones in skeletal health are well established, the associations of vitamin D and its metabolites to sex hormones and their indices are less investigated. In this observational study, clinical information of 189 Saudi postmenopausal women aged ≥50 years old [N = 80 with normal bone mineral density (BMD), aged 53.3 ± 7.7 years with body mass index (BMI)= 34.1kg/m2 ± 5.8, and N = 109 with low BMD (T-score −1.0 to −2.5), aged 57.0 ± 8.2 years, BMI = 32.4kg/m2 ± 6.2] was extracted from an existing capital-wide osteoporosis registry in Riyadh, Saudi Arabia. Data included were BMD scores, serum total 25(OH)D, sex hormones, and bone turnover markers which were measured using commercially available assays. Age- and BMI-adjusted comparisons revealed significantly higher parathyroid hormone (PTH) levels as well as significantly lower testosterone and bioavailable testosterone in the low BMD group than the normal BMD group (p-values 0.04, 0.02, and 0.03, respectively). Stepwise linear regression showed that circulating testosterone levels accounted for 9.7% and 8.9% of the variances perceived in bioavailable 25(OH)D and free 25(OH)D, respectively (p < 0.01), independent of other sex hormones, sex hormone indices, and bone turnover markers. Our study suggests that androgens are significantly associated with non-conventional vitamin D metabolites and these associations may have clinical relevance in assessing risk for low BMD and osteoporosis in Arab postmenopausal women.

Vitamin D3 analogs for the treatment of osteoporosis

2015 ◽  
Vol 93 (5) ◽  
pp. 327-332 ◽  
Author(s):  
Hiroshi Hagino
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Mineral Density ◽  
Double Blind ◽  
Treatment Of Osteoporosis ◽  
Dihydroxyvitamin D ◽  
Ovx Rats ◽  
Turnover Markers

Vitamin D supplementation is recommended whenever patients are given therapeutic drugs for osteoporosis, to make their calcium (Ca) balance positive. Vitamin D is converted to 25-hydroxyvitamin D in the liver, and then activated to become 1α,25-dihydroxyvitamin D in the kidneys. The active vitamin D acts in the intestine to stimulate Ca absorption and maintain the Ca balance. 2β-(3-Hydroxypropyloxy)-1α,25-dihydroxyvitamin D3 (eldecalcitol) and 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 (2MD) are newly developed vitamin D analogs, with a substitution at the 2 position of 1α,25-dihydroxyvitamin D3 (calcitriol). Eldecalcitol and 2MD share common structural and biological characteristics. Both compounds increase serum Ca levels more markedly than calcitriol, increase bone mineral density (BMD), and improve bone strength in ovariectomized (OVX) rats. In a randomized, placebo-controlled, double-blind, 1 year clinical trial, eldecalcitol dose-dependently increased lumbar and hip BMD and suppressed bone turnover markers in patients with osteoporosis. Whereas, 2MD markedly increased the bone turnover markers, but it did not change the BMD of postmenopausal women with osteopenia in a 1 year clinical trial. After a randomized, double-blind, 3 year fracture-prevention trial comparing it with alfacalcidol, eldecalcitol was approved for the treatment of osteoporosis in Japan. On the other hand, the manufacturer discontinued the clinical development of 2MD. In this review, we discuss the similarities and differences between these 2 compounds, and the reasons why different outcomes resulted from their clinical trials.

scholarly journals Influence of Vitamin D Status on the Effect of Statins on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women

2014 ◽  
Vol 99 (9) ◽  
pp. 3304-3309 ◽  
Author(s):  
José L. Hernández ◽  
José M. Olmos ◽  
Galo Romaña ◽  
Javier Llorca ◽  
Josefina Martínez ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Vitamin D Status ◽  
Mineral Density ◽  
Turnover Markers

scholarly journals Serum 25-OH Vitamin D in relation to Bone Mineral Density and Bone Turnover

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Nicola Napoli ◽  
Rocky Strollo ◽  
Delia Sprini ◽  
Ernesto Maddaloni ◽  
Giovam Battista Rini ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Femoral Neck ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Mineral Density ◽  
Serum 25Ohd ◽  
Turnover Markers

It is unclear which vitamin D status is optimal for bone health. In this study, we aimed to assess cutoffs of 25-hydroxyvitamin D (25OHD) derived by the literature (20, 25, or 30 ng/mL) in relation to bone turnover and bone mineral density (BMD). Serum 25OHD, PTH, osteocalcin, bone alkaline phosphatase, and C-telopeptide were measured in 274 consecutive postmenopausal women. BMD of the lumbar spine (L1–L4) and of femoral neck were also evaluated. 50 patients had normal BMD, while 124 had osteopenia and 100 had osteoporosis. 37.6%, 56.2%, and 70.8% subjects had serum 25OHD lower than 20, 25, or 30 ng/mL, respectively. No differences in bone turnover markers were found when comparing patients with low 25OHD defined according to the different cutoffs. However, a cutoff of 25 ng/mL appeared to differentiate better than a cutoff of 30 ng/mL in those subjects with reduced femoral neck BMD. The PTH plateau occurred at 25OHD levels of 26–30 ng/mL. In conclusion, vitamin D deficiency is common in Sicilian postmenopausal women and it may be associated with low BMD and increased bone turnover markers. Further studies are needed to better define the right cutoff for normal vitamin D levels in postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document